tazarotene has been researched along with Atrophy in 2 studies
tazarotene: a topical acetylenic retinoid; a topical kerytolytic
tazarotene : The ethyl ester of tazarotenic acid. A prodrug for tazarotenic acid, it is used for the treatment of psoriasis, acne, and sun-damaged skin.
Atrophy: Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "1% significantly reduces epidermal atrophy induced by diflorasone diacetate 0." | 9.09 | A pilot study to determine the effect of tazarotene gel 0.1% on steroid-induced epidermal atrophy. ( Gibson, JR; Kaidbey, K; Kopper, SC; Sefton, J, 2001) |
| "By contrast, median qualitative acne scar scores were the same for both treatment groups at baseline and did not significantly change following either treatment." | 6.90 | Topical Tazarotene Gel, 0.1%, as a Novel Treatment Approach for Atrophic Postacne Scars: A Randomized Active-Controlled Clinical Trial. ( Afra, TP; Dogra, S; Kumar, A; Narang, T; Razmi T, M, 2019) |
| "1% significantly reduces epidermal atrophy induced by diflorasone diacetate 0." | 5.09 | A pilot study to determine the effect of tazarotene gel 0.1% on steroid-induced epidermal atrophy. ( Gibson, JR; Kaidbey, K; Kopper, SC; Sefton, J, 2001) |
| "By contrast, median qualitative acne scar scores were the same for both treatment groups at baseline and did not significantly change following either treatment." | 2.90 | Topical Tazarotene Gel, 0.1%, as a Novel Treatment Approach for Atrophic Postacne Scars: A Randomized Active-Controlled Clinical Trial. ( Afra, TP; Dogra, S; Kumar, A; Narang, T; Razmi T, M, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afra, TP | 1 |
| Razmi T, M | 1 |
| Narang, T | 1 |
| Dogra, S | 1 |
| Kumar, A | 1 |
| Kaidbey, K | 1 |
| Kopper, SC | 1 |
| Sefton, J | 1 |
| Gibson, JR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Microneedling Versus Topical Tazarotene 0.1% Gel for the Treatment of Atrophic Post Acne Scarring - a Randomized Controlled Study[NCT03170596] | 36 participants (Actual) | Interventional | 2017-06-02 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for tazarotene and Atrophy
| Article | Year |
|---|---|
Topical Tazarotene Gel, 0.1%, as a Novel Treatment Approach for Atrophic Postacne Scars: A Randomized Active-Controlled Clinical Trial.
Topics: Acne Vulgaris; Administration, Topical; Adult; Atrophy; Cicatrix; Cosmetic Techniques; Dermatologic | 2019 |
A pilot study to determine the effect of tazarotene gel 0.1% on steroid-induced epidermal atrophy.
Topics: Adrenal Cortex Hormones; Adult; Atrophy; Betamethasone; Biopsy; Dermatologic Agents; Double-Blind Me | 2001 |